Eli Lilly and Company $LLY Stock Holdings Lessened by Blue Trust Inc.

Blue Trust Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 89,627 shares of the company’s stock after selling 484 shares during the period. Eli Lilly and Company comprises about 0.8% of Blue Trust Inc.’s portfolio, making the stock its 23rd largest holding. Blue Trust Inc.’s holdings in Eli Lilly and Company were worth $68,385,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Sheets Smith Wealth Management boosted its position in shares of Eli Lilly and Company by 1.7% in the 3rd quarter. Sheets Smith Wealth Management now owns 14,423 shares of the company’s stock valued at $11,004,000 after purchasing an additional 237 shares during the period. Avanza Fonder AB raised its holdings in Eli Lilly and Company by 8.9% during the 3rd quarter. Avanza Fonder AB now owns 2,593 shares of the company’s stock worth $1,978,000 after buying an additional 212 shares during the period. Randall & Associates Wealth Management purchased a new stake in Eli Lilly and Company during the third quarter valued at about $236,000. Scott Capital Advisors LLC lifted its stake in Eli Lilly and Company by 6.6% during the third quarter. Scott Capital Advisors LLC now owns 822 shares of the company’s stock valued at $695,000 after buying an additional 51 shares in the last quarter. Finally, CWM LLC boosted its holdings in shares of Eli Lilly and Company by 11.1% in the third quarter. CWM LLC now owns 98,555 shares of the company’s stock worth $75,198,000 after buying an additional 9,812 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 0.0%

NYSE LLY opened at $1,077.26 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The firm’s fifty day simple moving average is $986.75 and its 200-day simple moving average is $841.14. The company has a market capitalization of $1.02 trillion, a PE ratio of 52.70, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the previous year, the company posted $1.18 earnings per share. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 33.86%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on LLY shares. BMO Capital Markets set a $1,200.00 price target on shares of Eli Lilly and Company in a report on Thursday, December 4th. Scotiabank initiated coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 target price on the stock. UBS Group restated a “neutral” rating on shares of Eli Lilly and Company in a report on Thursday, December 18th. The Goldman Sachs Group lifted their price target on Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Wells Fargo & Company increased their price objective on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,155.36.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.